Topics

Phase 1 interim results for anti-BCMA CAR T-cell therapy in relapse refractory multiple myeloma

05:56 EDT 3 May 2019 | ecancermedicalscience

Interim results from CRB-401, an ongoing phase 1 study of bb2121 - a BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy candidate for patients with relapsed and refractory multiple myeloma - were published in the New England Journal of Medicine...

Original Article: Phase 1 interim results for anti-BCMA CAR T-cell therapy in relapse refractory multiple myeloma

NEXT ARTICLE

More From BioPortfolio on "Phase 1 interim results for anti-BCMA CAR T-cell therapy in relapse refractory multiple myeloma"

Quick Search